134 related articles for article (PubMed ID: 29045039)
1. Design of potent B-Raf
Wang ZF; Wang PF; Ma JT; Chai YZ; Hu HM; Gao WL; Wang ZC; Wang BZ; Zhu HL
Chem Biol Drug Des; 2018 Feb; 91(2):567-574. PubMed ID: 29045039
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of new B-Raf
Wang PF; Zhang YJ; Wang D; Hu HM; Wang ZC; Xu C; Qiu HY; Zhu HL
Bioorg Med Chem; 2018 May; 26(9):2372-2380. PubMed ID: 29602674
[TBL] [Abstract][Full Text] [Related]
3. Identification and Biological Evaluation of Novel Type II B-Raf
Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
[TBL] [Abstract][Full Text] [Related]
4. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
5. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.
Baska F; Szabadkai I; Sipos A; Breza N; Szántai-Kis C; Kékesi L; Garamvölgyi R; Nemes Z; Baska F; Neumann L; Torka R; Ullrich A; Kéri G; Orfi L
Curr Med Chem; 2014 Jun; 21(17):1938-55. PubMed ID: 24606495
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
8. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Yao H; Sun Q; Zhu J
Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
[TBL] [Abstract][Full Text] [Related]
9. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
[TBL] [Abstract][Full Text] [Related]
10. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
11. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
12. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
13. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel B-Raf
Wang PF; Qiu HY; Wang ZF; Zhang YJ; Wang ZC; Li DD; Zhu HL
Biochem Pharmacol; 2017 May; 132():63-76. PubMed ID: 28267440
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
Yang Y; Qin J; Liu H; Yao X
J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
[TBL] [Abstract][Full Text] [Related]
17. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
18. An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors.
Xie H; Li Y; Yu F; Xie X; Qiu K; Fu J
Int J Mol Sci; 2015 Nov; 16(11):27350-61. PubMed ID: 26580609
[TBL] [Abstract][Full Text] [Related]
19. Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.
Xu Z; Yan G; Wang G; Li B; Zhu J; Sun P; Zhang X; Luo C; Wang H; Zhu W
Bioorg Med Chem Lett; 2012 Sep; 22(17):5428-37. PubMed ID: 22858139
[TBL] [Abstract][Full Text] [Related]
20. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
